Polymorphism of debrisoquine oxidation in New Zealand Caucasians

Abstract

Debrisoquine and sparteine are the most common markers used for the studies of oxidation phenotyping in human population. Two oxidation phenotypes have been clearly defined: extensive metabolizers (EM) and poor metabolizers (PM). The incidence of the PM phenotype appears to vary between ethnic groups [1]. In Caucasian populations, the frequency of PM ranges from 3 % in a Swedish population [2] to 10 % in a Swiss population [3]. From collected European data based on 5005 determinations, the mean frequency of debrisoquine PM was reported as 7.65 % [4]. The incidence of defective debrisoquine/sparteine oxidation in non-Caucasians appears to be lower than that observed in Caucasian groups. The PM phenotype frequency in Saudi Arabians and Egyptians is 1.0 and 1.4 %, respectively [5, 6]. This is also true for the Asian populations in which no PM of debrisoquine were found in studies of Japanese and Singaporean populations [7, 8], with an incidence of only 0.7 % in Chinese, 1.1% in Thai and 2.1% in Malaysians [8-10]. To our knowledge, no data is available for New Zealand populations, especially for the Polynesian ethnic groups, i.e., Maori and South Pacific polynesians. This study was conducted as part of an investigation to determine the incidence of oxidation phenotype in New Zealand populations. Oxidation phenotyping was carried out in 111 healthy New Zealand Caucasian volunteers. All subjects gave informed consent and the protocol was approved by the Otago Area Health Board Ethical Committee, Dunedin, New Zealand. Subjects were aged between 18 and 57 y (mean: 24 (7) (SD)) and they included 63 m and48 f. They took no medication for at least 1 week before the study. The subjects took a single oral dose of debrisoquine sulphate (10 rag) in the morning, after voiding their bladders. Urine was then collected for the following 4 h and was analysed for debrisoquine and its major metabolite 4-hydroxydebrisoquine by HPLC [11, 12]. The metabolic ratio (MR) was calculated as: % dose eliminated as debrisoquine % dose eliminated as 4-hydroxydebrisoquine

DOI: 10.1007/BF00266364

Statistics

05001000'99'01'03'05'07'09'11'13'15'17
Citations per Year

141 Citations

Semantic Scholar estimates that this publication has 141 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wanwimolruk1992PolymorphismOD, title={Polymorphism of debrisoquine oxidation in New Zealand Caucasians}, author={Sompon Wanwimolruk and John R Denton and D. G. Ferry and Matthew Beasley and John R Broughton}, journal={European Journal of Clinical Pharmacology}, year={1992}, volume={42}, pages={349-350} }